Literature DB >> 1800703

Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.

A T Serajuddin1, S A Ranadive, E M Mahoney.   

Abstract

The apparent octanol-water partition coefficients (Po/w) and aqueous solubilities for four 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors [pravastatin, lovastatin (mevinolin), mevastatin (compactin), and simvastatin (synvinolin)] were compared. Pravastatin is highly hydrophilic compared with lovastatin, mevastatin, or simvastatin. Pravastatin is clinically used as the active hydroxy acid, while the other three compounds are administered as prodrug lactones which, over a period of time, convert in vivo to their respective active hydroxy acid forms. The order of the Po/w values of the hydroxy acid forms was pravastatin much less than mevastatin less than lovastatin less than simvastatin at each pH evaluated, with approximate ratios of 1:25:75:200, respectively. The relative order and the ratios of partition coefficients for the lactone forms were similar to those for the hydroxy acid forms. In addition, lovastatin, mevastatin, and simvastatin are virtually insoluble in water, with solubility values ranging from 0.0013 to 0.0015 mg/mL at 23 degrees C. In comparison, pravastatin is hydrophilic, as demonstrated by the greater than 100-fold greater solubility of its lactone form (0.18 mg/mL). The greater hydrophilicity of pravastatin may explain its reported lower permeation into nonhepatic cells and the selectivity with respect to inhibition of cholesterol synthesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1800703     DOI: 10.1002/jps.2600800905

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  36 in total

1.  Pharmacokinetic and pharmacodynamic evaluation for tissue-selective inhibition of cholesterol synthesis by pravastatin.

Authors:  T Hatanaka; S Honda; S Sasaki; K Katayama; T Koizumi
Journal:  J Pharmacokinet Biopharm       Date:  1998-06

Review 2.  Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms.

Authors:  A S Callahan
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

3.  Simvastatin induces a central hypotensive effect via Ras-mediated signalling to cause eNOS up-regulation.

Authors:  Wen-Han Cheng; Wen-Yu Ho; Chien-Feng Chang; Pei-Jung Lu; Pei-Wen Cheng; Tung-Chen Yeh; Ling-Zong Hong; Gwo-Ching Sun; Michael Hsiao; Ching-Jiunn Tseng
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

4.  Impact of CYP2D6 polymorphisms on the pharmacokinetics of lovastatin in Chinese subjects.

Authors:  Ophelia Qi Ping Yin; Valiant Wah Lun Mak; Miao Hu; Benny Siu Pong Fok; Moses Sing Sum Chow; Brian Tomlinson
Journal:  Eur J Clin Pharmacol       Date:  2012-01-27       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.

Authors:  J P Desager; Y Horsmans
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

6.  Local Application of Pyrophosphorylated Simvastatin Prevents Experimental Periodontitis.

Authors:  Xiaobei Wang; Zhenshan Jia; Yosif Almoshari; Subodh M Lele; Richard A Reinhardt; Dong Wang
Journal:  Pharm Res       Date:  2018-06-25       Impact factor: 4.200

7.  Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport.

Authors:  Jonathan B Wagner; Melissa Ruggiero; J Steven Leeder; Bruno Hagenbuch
Journal:  Drug Metab Dispos       Date:  2020-09-05       Impact factor: 3.922

Review 8.  Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Authors:  Jonathan Wagner; Susan M Abdel-Rahman
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

9.  Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.

Authors:  T Yada; M Nakata; T Shiraishi; M Kakei
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

10.  In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

Authors:  A Saheki; T Terasaki; I Tamai; A Tsuji
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.